Description

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Pep Gubau, CEO, CTO & Co-Founder at Aizon.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Pep, covering:

• How working out what not to do very early on led to two successful growth and exit stories.
• Why surrounding yourself with smarter people is essential to learning, scaling, and long term success.
• How the industry’s underuse of data led to the creation of Aizon, and the challenge of pitching AI back in 2014 when it was anything but fashionable.
• The critical difference between pharma people building technology versus technology companies trying to do pharma.
• How pharma and CDMO manufacturing teams should be thinking about digitisation, AI, and transformative technology in a practical, value driven way.

Pep Gubau is the CEO and co-founder of Aizon, and a seasoned tech entrepreneur with four decades of experience and two previously successful companies.

He has a unique background as an economist with a foundation in engineering, and he holds several international patents in encryption, data transmission, storage, and processing for regulated cloud environments.

Pep is also a frequent speaker on the impact of Big Data, Machine Learning, and other Artificial Intelligence technologies, sharing insights into how these innovations are transforming regulated industries.

Molecule to Market is also sponsored by Bora Pharmaceuticals, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!